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Corrections
M Dougados, J Braun, S Szanto, et al. Efﬁ  cacy of etanercept on rheumatic signs and pulmonary 
function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-
controlled study (SPINE). Ann Rheum Dis 2011;70:799–804 doi:10.1136/ard.2010.139261. The data 
published for ASDAS-CRP status at W12 in Table 2 is incorrect. The data provided was the % 
of patients with changes during the study and not the % of patients at the end of the study. The 
correct table appears below:
Ann Rheum Dis 2011;70:1349. doi.10.1136/ard.2010.139261corr1
Table 2  Responder criteria after 12 weeks of therapy by treatment group
Treatment group
 Responder criteria Placebo (n=43) Etanercept (n=39)    p value
ASAS20 14 (33%) 25 (67%)     0.003
ASAS40 10 (23%) 17 (44%)     0.053
ASAS5/6   2 (5%)   8 (21%)     0.044
ASAS partial remission   2 (5%)   7 (18%)     0.073
BASDAI 50 10 (23%) 18 (46%)     0.031
ASDAS-CRP changes (W12-baseline)
 ASDAS  ≥1.1 (minimally important 
improvement)
  7 (17.1) 25 (64.1) <0.0001
 ASDAS  ≥2.0 (major improvement)   1 (2.4) 15 (38.5) <0.0001
ASDAS-CRP status at W12
  ASDAS <1.3    2 (4.7%)   5 (12.8%)     0.249
 ASDAS  <2.1   5  (11.6%) 16 (41.0%)     0.005
ASAS = Ankylosing Spondylitis Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, ASDAS = Ankylosing 
Spondylitis Disease Activity Score
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